Ipilumab plus nivolumab shows efficacy in resected stage IV melanoma
Encouraging results for adjuvant immunotherapy with nivolumab (NIVO) in combination with ipilimumab (IPI) have been reported today at ESMO Congress 2019, according to Caroline Robert, Institut Gustave Roussy, Villejuif, France. The phase II IMMUNED trial…
Watch Here